Position in NVAX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$203
+$35 QoQ
Shares Held
25
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Caitlin John, LLC holds $329,830 across 21 Biotechnology names. NVAX ranks #16 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
4,302 | $278,037 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
31 | $13,842 | |
| 3 | DRTS |
Alpha Tau Medical Ltd.
|
1,765 | $12,478 | |
| 4 | GTBP |
GT Biopharma, Inc.
|
16,500 | $6,732 | |
| 5 | NAGE |
Niagen Bioscience, Inc.
|
1,100 | $4,851 | |
| 6 | IBRX |
ImmunityBio, Inc.
|
500 | $3,835 | |
| 7 | ARGX |
Argenx SE
|
3 | $2,190 | |
| 8 | INSM |
INSMED Inc
|
10 | $1,635 |
All Filings in NVAX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $203 | 25 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $168 | 25 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $216 | 25 | Shares | Sole | 2025-11-12 | |
| 2024-12-31 | $201 | 25 | Shares | Sole | 2025-01-27 | |
| 2024-09-30 | $315 | 25 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $316 | 25 | Shares | Sole | 2025-01-27 | |
| 2024-03-31 | $119 | 25 | Shares | Sole | 2025-01-27 | |
| 2023-12-31 | $120 | 25 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||